Progress in immunotherapy for advanced soft tissue sarcoma

In G K, Hu J S, Tseng W W. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations[J]. Ther Adv Med Oncol, 2017, 9(8): 533-550. doi: 10.1177/1758834017712963

Zwelling L A, Silberman L, Estey E. Intercalator-induced, topoisomerase Ⅱ-mediated DNA cleavage and its modification by antineoplastic antimetabolites[J]. Int J Radiat Oncol Biol Phys, 1986, 12(7): 1041-1047. doi: 10.1016/0360-3016(86)90222-1

Vlenterie M, Litière S, Rizzo E, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European organisation for research and treatment of cancer soft tissue and bone sarcoma group; setting a new landmark for studies in this entity[J]. Eur J Cancer, 2016, 58: 62-72. doi: 10.1016/j.ejca.2016.02.002

Jones R L, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy[J]. Eur J Cancer, 2005, 41(18): 2853-2860. doi: 10.1016/j.ejca.2005.07.023

Fury M G, Antonescu C R, Van Zee K J, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy[J]. Cancer J, 2005, 11(3): 241-247. doi: 10.1097/00130404-200505000-00011

Raney B, Evans A, Granowetter L, et al. Nonsurgical management of children with recurrent or unresectable fibromatosis[J]. Pediatrics, 1987, 79(3): 394-398. http://www.sciencedirect.com/science/article/pii/S0022534717426851

Van Glabbeke M, Van Oosterom A T, Oosterhuis J W, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2, 185 patients treated with anthracycline-containing first-line regimens: a European organization for research and treatment of cancer soft tissue and bone sarcoma group study[J]. J Clin Oncol, 1999, 17(1): 150-157. doi: 10.1200/JCO.1999.17.1.150

Le Cesne A, Blay J Y, Judson I, et al. Phase Ⅱ study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial[J]. J Clin Oncol, 2005, 23(3): 576-584. doi: 10.1200/JCO.2005.01.180

Samuels B L, Chawla S P, Somaiah N, et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma[J]. Cancer, 2017, 123(23): 4640-4647. doi: 10.1002/cncr.30926

Blay J Y, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)[J]. Ann Oncol, 2008, 19(4): 821-822. doi: 10.1093/annonc/mdn033

Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2018, 19(5): 639-648. doi: 10.1016/S1470-2045(18)30143-8

Gounder M M, Mahoney M R, Van Tine B A, et al. Sorafenib for advanced and refractory desmoid tumors[J]. N Engl J Med, 2018, 379(25): 2417-2428. doi: 10.1056/NEJMoa1805052

Bissler J J, McCormack F X, Young L R, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis[J]. N Engl J Med, 2008, 358(2): 140-151. doi: 10.1056/NEJMoa063564

Corless C L, Ballman K V, Antonescu C R, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial[J]. J Clin Oncol, 2014, 32(15): 1563-1570. doi: 10.1200/JCO.2013.51.2046

Wilky B A, Goldberg J M. Immunotherapy in sarcoma: a new frontier[J]. Discov Med, 2014, 17(94): 201-206. http://www.ncbi.nlm.nih.gov/pubmed/24759624

Burgess M, Gorantla V, Weiss K, et al. Immunotherapy in sarcoma: future horizons[J]. Curr Oncol Rep, 2015, 17(11): 52-52. doi: 10.1007/s11912-015-0476-7

Pollack S M, Jungbluth A A, Hoch B L, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma[J]. Cancer, 2012, 118(18): 4564-4570. doi: 10.1002/cncr.27446

Lai J P, Rosenberg A Z, Miettinen M M, et al. NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target[J]. Oncoimmunology, 2012, 1(8): 1409-1410. doi: 10.4161/onci.21059

Li Q S, Rao R, Vazzana J, et al. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity[J]. J Immunol, 2012, 188(7): 3080-3087. doi: 10.4049/jimmunol.1103365

Burgess M, Tawbi H. Immunotherapeutic approaches to sarcoma[J]. Curr Treat Options Oncol, 2015, 16(6): 26-26. doi: 10.1007/s11864-015-0345-5

Chang H R, Cordon-Cardo C, Houghton A N, et al. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas[J]. Cancer, 1992, 70(3): 633-638. doi: 10.1002/1097-0142(19920801)70:3<633::AID-CNCR2820700315>3.0.CO;2-F

Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma[J]. Oncogene, 2001, 20(40): 5755-5762. doi: 10.1038/sj.onc.1204601

Kawaguchi S, Tsukahara T, Ida K, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group[J]. Cancer Sci, 2012, 103(9): 1625-1630. doi: 10.1111/j.1349-7006.2012.02370.x

Robbins P F, Morgan R A, Feldman S A, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J]. J Clin Oncol, 2011, 29(7): 917-924. doi: 10.1200/JCO.2010.32.2537

Mitsis D, Francescutti V, Skitzki J. Current immunotherapies for sarcoma: clinical trials and rationale[J]. Sarcoma, 2016, 2016: 1-6. http://europepmc.org/articles/PMC5039267/

Tsushima F, Yao S, Shin T, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy[J]. Blood, 2007, 110(1): 180-185. doi: 10.1182/blood-2006-11-060087

Torabi A, Amaya C N, Wians F H Jr, et al. PD-1 and PD-L1 expression in bone and soft tissue sarcomas[J]. Pathology, 2017, 49(5): 506-513. doi: 10.1016/j.pathol.2017.05.003

Bertucci F, Finetti P, Perrot D, et al. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas[J]. Oncoimmunology, 2017, 6(3): e1278100. doi: 10.1080/2162402X.2016.1278100

Budczies J, Mechtersheimer G, Denkert C, et al. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma[J]. Oncoimmunology, 2017, 6(3): e1279777. doi: 10.1080/2162402X.2017.1279777

Tawbi H A, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial[J]. Lancet Oncol, 2017, 18(11): 1493-1501. doi: 10.1016/S1470-2045(17)30624-1

Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas[J]. Clin Sarcoma Res, 2016, 6: 24-24. doi: 10.1186/s13569-016-0064-0

Ben-Ami E, Barysauskas C M, Solomon S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study[J]. Cancer, 2017, 123(17): 3285-3290. doi: 10.1002/cncr.30738

D′Angelo S P, Mahoney M R, van Tine B A, et al. A multi-center phase Ⅱ study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)[J]. J Clin Oncol, 2017, 35(15suppl): 11007-11013. http://www.researchgate.net/publication/327489254_A_multi-center_phase_II_study_of_nivolumab_-_ipilimumab_for_patients_with_metastatic_sarcoma_Alliance_A091401